

## Special Issue

# Editorial Board Members' Collection Series: Recent Advancements in Malignant Parotid Tumors

### Message from the Guest Editors

Salivary gland malignancies are rare, heterogeneous, and diverse, constituting 1–3% of head–neck tumors. Clinical course varies according to a diverse range of histological and clinical behaviors, ranging from indolent, slow-growing adenoid cystic carcinoma to rapidly progressive, possibly fatal, salivary ductal carcinoma. In this Special Issue on “Editorial Board Members' Collection Series: Recent Advancements in Malignant Parotid Tumors”, we encourage original research or review articles on the wide range of topics related to parotid tumor, from epidemiology histology and genetic translocation to clinical management, including surgery and radiation therapy, chemotherapy, and novel therapeutics, such as molecular targeted therapies.

---

### Guest Editors

**Dr. Raffaele Addeo**

Medical Oncology Unit, San Giovanni di Dio Hospital, 80027 Frattamaggiore, Naples, Italy

**Dr. Pierre Yves Marcy**

Department of Radiodiagnostics and Interventional Imaging, Polyclinics ELSAN Group, PolyClinics Les Fleurs, Quartier Quiez, 83189 Ollioules, France

---

### Deadline for manuscript submissions

closed (30 September 2023)



## Current Oncology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 4.9  
Indexed in PubMed



[mdpi.com/si/147578](https://mdpi.com/si/147578)

*Current Oncology*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[currentoncology@mdpi.com](mailto:currentoncology@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[curroncol](https://currentoncology.com)





# Current Oncology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 4.9  
Indexed in PubMed



[mdpi.com/journal/  
currentcol](https://mdpi.com/journal/currentcol)



## About the Journal

### Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

---

### Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology)